Vasopressor resident survival guide: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Sepsis}} {{CMG}}; {{AE}} {{AZ}} ==Definition== ==Causes== ===Life Threatening Causes=== ===Common Causes=== ===Prognosis=== ==Management== {{Family tree/s...")
 
 
(29 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Sepsis}}
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==Definition==
==Overview==
 
==Causes==
 
===Life Threatening Causes===
 
===Common Causes===
 
 
===Prognosis===
 


==Management==
==Management==
 
{| class="wikitable"
{{Family tree/start}}
|-
{{Family tree | | | | | | | | | | | | | A01 | | | | | | | |A01= '''Vasopressors'''}}
| ||'''[[Norepinephrine]]''' || '''[[Dopamine]]''' || '''[[Vasopressin]]''' || '''[[Phenylephrine]]''' ||'''[[Dobutamine]]'''
{{Family tree | | | | | | | | | | | | | |!| | | | | | | | }}
|-
{{Family tree | | | | | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | }}
| '''Mechanism''' || Mainly predominant'''α1''' agonist (Vasoconstrictive) <br> *some β1 agonist (↑contractility) || *Mainly predominant '''β1''' agonist (↑ cardiac contractility) <br> * some α1 agonist(Vasoconstrictive)|| *'''V<sub></sub>1''' receptor of GIT vasculatures <br> *Antidiuretic effects || *'''Pure α1''' agonist(Vasoconstrictive) <br> *No β1 || *Predominant '''β1''' agonist (↑contractility) <br> *β2 arterial smooth muscle (Hypotensive)
{{Family tree | | | | | B01 | | B02 | | B03 | | B04 | | B05 | = }}
|-
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | }}
| '''Indication''' || *'''1st''' line in : <br> *'''Septic shock''' <br> *'''Cardiogenic shock''' <br>*Undifferentiated shock || 2nd line septic shock || 2nd line septic shock || '''1st''' line '''Neurogenic shock''' <BR> 3rd-4th line septic shock || *1st line '''cardiogenic shock''' <BR>* low output septic shock
 
|-
{{Family tree/end}}
| '''Dose''' || 1-30 mcg/min <br>0.01-0.3mcg/kg/min || 2-20 mcg/min || 0.03 unit/min || 20-300 mcg/kg/min || 2.5-20 mcg/kg/min
|-
| '''Complications''' || Tachyarrhythmia {less β1 effect} <br>( less than Dopamine ) || Arrhythmia (more β1)  || *Coronary spasm<br>*Splanchnic vasoconstriction|| Reflex bradycardia <br>(only α1) || Hypotension (β2)
|-
| '''Cautions''' || Arrhythmia || *'''Not in cardiogenic shock''' <br>*Arrhythmia <br> *Ischemia induced cardiotoxicity || *Ischemic heart <br> *Gut ischemia || *Bradycardia <br> *Heart block ||*Hypotension (add α1 agonist)
|}


==Do's==
==Do's==
Line 30: Line 24:
:*Always volume fluid resuscitation first
:*Always volume fluid resuscitation first
:*Norepinephrine in undifferentiated shock.
:*Norepinephrine in undifferentiated shock.
:*Titrate dobutamine according to clinical response slowly ( 2-20 ug/kg/min ) to avoid tachycardia (10% increase from the baseline). The benefit that dobutamine has as minimal effect on myocardial oxygen demand is lost if it is not well titrated.


==Don'ts==
==Don'ts==
 
:* Do not start with low dose Dopamine dose to perfuse the kidney.


==References==
==References==

Latest revision as of 10:53, 13 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overview

Management

Norepinephrine Dopamine Vasopressin Phenylephrine Dobutamine
Mechanism Mainly predominantα1 agonist (Vasoconstrictive)
*some β1 agonist (↑contractility)
*Mainly predominant β1 agonist (↑ cardiac contractility)
* some α1 agonist(Vasoconstrictive)
*V1 receptor of GIT vasculatures
*Antidiuretic effects
*Pure α1 agonist(Vasoconstrictive)
*No β1
*Predominant β1 agonist (↑contractility)
*β2 arterial smooth muscle (Hypotensive)
Indication *1st line in :
*Septic shock
*Cardiogenic shock
*Undifferentiated shock
2nd line septic shock 2nd line septic shock 1st line Neurogenic shock
3rd-4th line septic shock
*1st line cardiogenic shock
* low output septic shock
Dose 1-30 mcg/min
0.01-0.3mcg/kg/min
2-20 mcg/min 0.03 unit/min 20-300 mcg/kg/min 2.5-20 mcg/kg/min
Complications Tachyarrhythmia {less β1 effect}
( less than Dopamine )
Arrhythmia (more β1) *Coronary spasm
*Splanchnic vasoconstriction
Reflex bradycardia
(only α1)
Hypotension (β2)
Cautions Arrhythmia *Not in cardiogenic shock
*Arrhythmia
*Ischemia induced cardiotoxicity
*Ischemic heart
*Gut ischemia
*Bradycardia
*Heart block
*Hypotension (add α1 agonist)

Do's

  • Assess the cause of shock
  • Always volume fluid resuscitation first
  • Norepinephrine in undifferentiated shock.
  • Titrate dobutamine according to clinical response slowly ( 2-20 ug/kg/min ) to avoid tachycardia (10% increase from the baseline). The benefit that dobutamine has as minimal effect on myocardial oxygen demand is lost if it is not well titrated.

Don'ts

  • Do not start with low dose Dopamine dose to perfuse the kidney.

References

Template:WH Template:WS